Suppr超能文献

利用干细胞和干细胞衍生的血管细胞构建组织工程血管移植物。

Fabrication of tissue-engineered vascular grafts with stem cells and stem cell-derived vascular cells.

作者信息

Wang Lunchang, Hu Jiang, Sorek Claire E, Chen Eugene Y, Ma Peter X, Yang Bo

机构信息

a Cardiac Surgery, University of Michigan , Ann Arbor , MI , USA.

b Vascular Surgery, The Second Xiangya Hospital , Xiangya School of Medicine, Central South University , Hunan , China.

出版信息

Expert Opin Biol Ther. 2016;16(3):317-30. doi: 10.1517/14712598.2016.1118460. Epub 2015 Dec 8.

Abstract

INTRODUCTION

Cardiovascular disease is the leading cause of mortality worldwide. Current surgical treatments for cardiovascular disease include vascular bypass grafting and replacement with autologous blood vessels or synthetic vascular grafts. However, there is a call for better alternative biological grafts.

AREAS COVERED

Tissue-engineered vascular grafts (TEVGs) are promising novel alternatives to replace diseased vessels. However, obtaining enough functional and clinically usable vascular cells for fabrication of TEVGs remains a major challenge. New findings in adult stem cells and recent advances in pluripotent stem cells have opened a new avenue for stem cell-based vascular engineering. In this review, recent advances on stem cell sourcing for TEVGs including the use of adult stem cells and pluripotent stem cells and advantages, disadvantages, and possible future implementations of different types of stem cells will be discussed. In addition, current strategies used during the fabrication of TEVGs will be highlighted.

EXPERT OPINION

The application of patient-specific TEVGs constructed with vascular cells derived from immune-compatible stem cells possesses huge clinical potential. Advances in lineage-specific differentiation approaches and innovative vascular engineering strategies will promote the vascular regeneration field from bench to bedside.

摘要

引言

心血管疾病是全球主要的死亡原因。目前心血管疾病的外科治疗方法包括血管旁路移植术以及使用自体血管或人工血管进行置换。然而,人们呼吁采用更好的替代性生物移植物。

涵盖领域

组织工程血管移植物(TEVG)是替代病变血管的有前景的新型选择。然而,获取足够数量的功能性且可用于临床的血管细胞以制造TEVG仍然是一项重大挑战。成体干细胞的新发现以及多能干细胞的最新进展为基于干细胞的血管工程开辟了一条新途径。在本综述中,将讨论TEVG干细胞来源的最新进展,包括成体干细胞和多能干细胞的使用,以及不同类型干细胞的优缺点和未来可能的应用。此外,还将重点介绍TEVG制造过程中目前使用的策略。

专家观点

应用由免疫兼容干细胞衍生的血管细胞构建的患者特异性TEVG具有巨大的临床潜力。谱系特异性分化方法和创新的血管工程策略的进展将推动血管再生领域从实验室走向临床应用。

相似文献

4
Tissue engineering vascular grafts a fortiori: looking back and going forward.组织工程血管移植物更是如此:回顾与展望。
Expert Opin Biol Ther. 2015 Feb;15(2):231-44. doi: 10.1517/14712598.2015.980234. Epub 2014 Nov 27.
9
Tissue Engineering: A Coupled Agent-Based Finite Element Approach.组织工程学:基于耦合代理的有限元方法。
Tissue Eng Part C Methods. 2019 Nov;25(11):641-654. doi: 10.1089/ten.TEC.2019.0103. Epub 2019 Sep 20.

引用本文的文献

本文引用的文献

2
8
A comparison of non-integrating reprogramming methods.非整合重编程方法的比较。
Nat Biotechnol. 2015 Jan;33(1):58-63. doi: 10.1038/nbt.3070. Epub 2014 Dec 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验